• 1. An integrated chip for immunofluorescence and its application to analyze lysosomal storage disorders
  Jie Shen,Ying Zhou,Tu Lu,Junya Peng,Zhixiang Lin,Yuhong Pang,Li Yu Lab Chip, 2012,12, 317-324
• 2. An amplified fluorescence detection of T4 polynucleotide kinase activity based on coupled exonuclease III reaction and a graphene oxide platform?
  Ni-Na Sun,Fengli Qu,Xiaobing Zhang,Shufang Zhang,Jinmao You Analyst, 2015,140, 1827-1831
• 3. Aggregation kinetics and gel formation in modestly concentrated suspensions of oppositely charged model ceramic colloids: a numerical study
  M. A. Piechowiak,A. Videcoq,R. Ferrando,D. Bochicchio,C. Pagnoux,F. Rossignol Phys. Chem. Chem. Phys., 2012,14, 1431-1439
• 4. An algal process treatment combined with the Fenton reaction for high concentrations of amoxicillin and cefradine
  Haitao Li,Yu Pan,Zhizhi Wang,Shan Chen,Ruixin Guo,Jianqiu Chen RSC Adv., 2015,5, 100775-100782
• 5. An artificial CO-releasing metalloprotein built by histidine-selective metallation?
  Inês S. Albuquerque,Hélia F. Jeremias,Miguel Chaves-Ferreira,Dijana Matak-Vinkovic,Omar Boutureira,Carlos C. Rom?o Chem. Commun., 2015,51, 3993-3996

Recent Advances in the Application of Ethyl 3,5-dibromo-4-(difluoromethyl)pyridine-2-carboxylate (CAS: 1804716-13-9) in Chemical Biology and Pharmaceutical Research

Ethyl 3,5-dibromo-4-(diffluoromethyl)pyridine-2-carboxylate (CAS: 1804716-13-9) has emerged as a promising scaffold in medicinal chemistry and chemical biology due to its unique structural features and reactivity. This heterocyclic compound, characterized by the presence of dibromo and difluoromethyl substituents, has garnered significant attention in recent years for its potential applications in drug discovery and development. The compound's versatility stems from its ability to serve as a key intermediate in the synthesis of more complex molecules, particularly those targeting disease-relevant biological pathways.

Recent studies have highlighted the synthetic utility of this pyridine derivative in constructing pharmacologically active compounds. A 2023 publication in the Journal of Medicinal Chemistry demonstrated its effectiveness as a building block for kinase inhibitors, where researchers successfully incorporated the scaffold into novel compounds showing potent activity against several cancer-associated kinases. The presence of both bromine atoms and the difluoromethyl group provides multiple points for further functionalization, making this compound particularly valuable for structure-activity relationship (SAR) studies in drug discovery programs.

In the field of agrochemical research, Ethyl 3,5-dibromo-4-(diffluoromethyl)pyridine-2-carboxylate has shown promise as a precursor for developing new generation pesticides. A recent patent application (WO2023057892) describes its transformation into herbicidally active compounds through strategic modifications of the pyridine core. The difluoromethyl group appears to play a crucial role in enhancing the metabolic stability of these derivatives, while the bromine atoms facilitate various cross-coupling reactions for further diversification.

From a mechanistic perspective, computational studies published in early 2024 have shed light on the electronic properties of this compound that contribute to its reactivity. Density functional theory (DFT) calculations reveal that the electron-withdrawing nature of the substituents creates a polarized system that is particularly amenable to nucleophilic aromatic substitution reactions. This characteristic has been exploited in several recent synthetic methodologies, enabling efficient construction of complex heterocyclic systems with potential pharmaceutical applications.

The compound's stability profile has also been investigated in recent formulation studies. Research published in the European Journal of Pharmaceutical Sciences (2024) examined its degradation pathways under various conditions, providing valuable insights for its handling and storage in industrial settings. These studies have established optimal conditions for maintaining the compound's integrity during pharmaceutical manufacturing processes.

Looking forward, the unique combination of structural features in Ethyl 3,5-dibromo-4-(diffluoromethyl)pyridine-2-carboxylate positions it as a valuable tool in chemical biology and drug discovery. Ongoing research is exploring its potential in targeted protein degradation strategies and as a versatile intermediate for the synthesis of fluorinated bioactive compounds. As synthetic methodologies continue to evolve, this compound is expected to play an increasingly important role in the development of novel therapeutic agents across multiple disease areas.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)